The DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index.
Second Malignant Neoplasms: Assessment and Strategies for Risk Reduction
Abstract
Improvements in early detection, supportive care, and treatment have resulted in an increasing number of cancer survivors, with a current 5-year relative survival rate for all cancers combined of approximately 66.1%. For some patients, these survival advances have been offset by the long-term late effects of cancer and its treatment, with second malignant neoplasms (SMNs) comprising one of the most potentially life-threatening sequelae. The number of patients with SMNs is growing, with new SMNs now representing about one in six of all cancers reported to the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program. SMNs reflect not only the late effects of therapy but also the influence of shared etiologic factors (in particular, tobacco and excessive alcohol intake), genetic susceptibility, environmental exposures, host effects, and combinations of factors, including gene-environment interactions. For selected SMNs, risk is also modified by age at exposure and attained age. SMNs can be categorized into three major groups according to the predominant etiologic factor(s): (1) treatment-related, (2) syndromic, and (3) those due to shared etiologic exposures, although the nonexclusivity of these groups should be underscored. Here we provide an overview of SMNs in survivors of adult-onset cancer, summarizing the current, albeit limited, clinical evidence with regard to screening and prevention, with a focus on the provision of guidance for health care providers. The growing number of patients with second (and higher-order) cancers mandates that we also further probe etiologic influences and genetic variants that heighten risk, and that we better define high-risk groups for targeted preventive and interventional clinical strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
The National Lung Screening Trial Research Team (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102873 · Cited by 11,064
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696
Renehan, A. G., Tyson, M., Egger, M., Heller, R. F., & Zwahlen, M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60269-x · Cited by 5,219
American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography
Saslow, D., Boetes, C., Burke, W., Harms, S., Leach, M. O., Lehman, C. D., Morris, E., Pisano, E., Schnall, M., Sener, S., et al. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.2.75 · Cited by 2,637
VASEN, H., WATSON, P., MECKLIN, J., & LYNCH, H. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70510-x · Cited by 2,519
From Cancer Patient to Cancer Survivor: Lost in Transition
(2005) · PsycEXTRA Dataset · doi:10.1037/e720092007-001 · Cited by 2,285
Vogel, V. G. (2006) · JAMA · doi:10.1001/jama.295.23.joc60074 · Cited by 1,652
Self-citationDomchek, S. M. (2010) · JAMA · doi:10.1001/jama.2010.1237 · Cited by 1,494
Cited by
Andersen, B. L., DeRubeis, R. J., Berman, B. S., Gruman, J., Champion, V. L., Massie, M. J., Holland, J. C., Partridge, A. H., Bak, K., Somerfield, M. R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.4611 · Cited by 735
Multiple primary tumours: challenges and approaches, a review
Vogt, A., Schmid, S., Heinimann, K., Frick, H., Herrmann, C., Cerny, T., & Omlin, A. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000172 · Cited by 628
Nekhlyudov, L., Mollica, M. A., Jacobsen, P. B., Mayer, D. K., Shulman, L. N., & Geiger, A. M. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djz089 · Cited by 416
Bodai, B. I., & Tuso, P. (2015) · The Permanente Journal · doi:10.7812/tpp/14-241 · Cited by 397
Lustberg, M. B., Kuderer, N. M., Desai, A., Bergerot, C., & Lyman, G. H. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00776-9 · Cited by 306
Metadata
- Authors
- Wood, M. E., Vogel, V., Ng, A., Foxhall, L., Goodwin, P., & Travis, L. B.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-10-20
- Volume
- 30
- Issue
- 30
- Pages
- 3734-3745
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1989412643
- Cited by
- 323
- References
- 119
- FWCI
- 12.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Second Malignant Neoplasms: Assessment and Strategies for Risk Reduction. https://app.cochat.ai/papers/10.1200/jco.2012.41.8681
- The paper
- Wood, M. E., Vogel, V., Ng, A., Foxhall, L., Goodwin, P., & Travis, L. B. (2012). Second Malignant Neoplasms: Assessment and Strategies for Risk Reduction. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2012.41.8681
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.